- 2009 Morgan Stanley Global Healthcare Unplugged Conference on
September 14th -
- ThinkEquity 6th Annual
Growth Conference: G6 on September 15th
–
- Banc of America Merrill Lynch Global Healthcare Conference on
September 16th -
- Webcasts Available Through Gilead Corporate Website -
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 11, 2009--
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the company
will be webcasting its corporate presentation at three upcoming investor
conferences: the 2009 Morgan Stanley Global Healthcare Unplugged
Conference in New York, the ThinkEquity 6th Annual Growth
Conference: G6 in San Francisco and the Banc of America Merrill Lynch
Global Healthcare Conference in London.
John F. Milligan, PhD, Gilead’s President and Chief Operating Officer,
along with Kevin Young, Gilead’s Executive Vice President, Commercial
Operations, will provide an overview of the company at the Morgan
Stanley conference on Monday, September 14 at 9:45 a.m. Eastern Daylight
Time (EDT).
Gregg H. Alton, Gilead’s Executive Vice President, Corporate and Medical
Affairs, will provide an overview of the company at the ThinkEquity
conference on Tuesday, September 15 at 9:30 a.m. Pacific Daylight Time
(12:30 p.m. EDT).
Dr. Milligan will provide an overview of the company at the Banc of
America Merrill Lynch Global Healthcare Conference on Wednesday,
September 16 at 11:20 a.m. British Summer Time (6:20 a.m. EDT).
To access the live webcasts via the internet log on to www.gilead.com.
Please connect to the company’s website at least 15 minutes prior to
each live presentation to ensure adequate time for any software download
that may be necessary to listen to the webcast.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company's mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com
or call the Gilead Public Affairs Department at 1-800-GILEAD-5
(1-800-445-3235).
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Susan Hubbard, 650-522-5715Investor
Relations
